Uruguayan firm Botica del Señor has launched a medicine derived from chamerion angustifolium to be used for the treatment of benign prostatic hyperplasia.
Uruguayan firm Botica del Señor has launched a medicine derived from chamerion angustifolium, a plant commonly known as fireweed or rosebay willowherb, to be used for the treatment of benign prostatic hyperplasia.
Pharmabiz attended the press conference held in the Uruguayan capital of Montevideo on Thursday.
The company highlighted its process of investigation and development, from the cultivation of the medicinal Chamerion angustifolium plant in Uruguay’s Canelones department, through to phase III clinical trials carried out with 60 patients.
Company director Walter Staininger said the process had taken seven years, from the project’s initial approval by Uruguay’s Technological Development Program through to the public health ministry’s certification of the medicine.
Of Austrian ancestry, the Staininger family has been in Uruguay since 1930. The family’s project was inspired by the considerable development of phytomedicine in Europe.
In conversation with Pharmabiz, the head of the company expressed high expectations for the new product, which he estimates will be available in pharmacies in Uruguay in the first half of 2015.
He said the company had not ruled out launching the product in Argentina or other countries in the region through the use of commercial agreements.
